Smoking and diabetes attenuate beneficial effects of PSCK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levels

BACKGROUND AND AIMS: Elevated lipoprotein (a) (Lp(a)) and low-density lipoprotein cholesterol levels (LDL-C) are significant residual risk factors for cardiovascular events. Treatment with protein convertase subtilisin kexin type 9 (PCSK9) inhibitors reduces the levels of both. Less is known about e...

Descripción completa

Detalles Bibliográficos
Autores principales: Rehberger Likozar, Andreja, Šebeštjen, Miran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833244/
https://www.ncbi.nlm.nih.gov/pubmed/36643800
http://dx.doi.org/10.1016/j.athplu.2022.07.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833244/
https://www.ncbi.nlm.nih.gov/pubmed/36643800
http://dx.doi.org/10.1016/j.athplu.2022.07.001

Ejemplares similares